US Health Care And "The Wisdom Of The Market"

11 May 1997

After the rejection of the Clinton health care reform plan, USRepublicans and Democrats are now introducing many bills that would implement portions of that plan, says a report for the right-wing group Citizens for a Sound Economy, which notes that each of these measures will write into law a piece of President Clinton's plan for government-run health care.

These bills will mean fewer choices for consumers, force unfunded federal mandates, set up standard benefits packages and establish new government bureaucracies that come between doctors and patients, says Michael Cannon, CSE health care policy analyst. Government already creates most problems in the health care system, and these will get worse with extra government involvement, he says.

Rather than take choices away from consumers, Congress should seek ways to return to them the choices that government has already removed, he says. He concedes that there are problems in the health insurance market, but attributes the high cost of quality health coverage to the government, which has driven up prices by imposing requirements on consumers and coverage providers. The bills now being proposed will further jeopardize consumers' health by causing health insurance costs to skyrocket, he says. Employers will drop coverage and many more consumers will lose their insurance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight